Search: onr:"swepub:oai:DiVA.org:uu-154914" >
Risk of Bleeding Wi...
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
-
Eikelboom, John W. (author)
-
- Wallentin, Lars, 1943- (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)
-
Connolly, Stuart J. (author)
-
show more...
-
Ezekowitz, Mike (author)
-
Healey, Jeff S. (author)
-
- Oldgren, Jonas, 1964- (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)
-
Yang, Sean (author)
-
Alings, Marco (author)
-
Kaatz, Scott (author)
-
Hohnloser, Stefan H. (author)
-
Diener, Hans-Christoph (author)
-
Franzosi, Maria Grazia (author)
-
Huber, Kurt (author)
-
Reilly, Paul (author)
-
Varrone, Jeanne (author)
-
Yusuf, Salim (author)
-
show less...
-
(creator_code:org_t)
- 2011
- 2011
- English.
-
In: Circulation. - 0009-7322 .- 1524-4539. ; 123:21, s. 2363-2372
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background-Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and Results-The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged = 75 years (4.43% versus 4.37%; P=0.89; P for interaction = 75 years (5.10% versus 4.37%; P=0.07; P for interaction = 75 years, intracranial bleeding risk is lower but extracranial bleeding risk is similar or higher with both doses of dabigatran compared with warfarin.
Keyword
- anticoagulants
- atrial fibrillation
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Eikelboom, John ...
-
Wallentin, Lars, ...
-
Connolly, Stuart ...
-
Ezekowitz, Mike
-
Healey, Jeff S.
-
Oldgren, Jonas, ...
-
show more...
-
Yang, Sean
-
Alings, Marco
-
Kaatz, Scott
-
Hohnloser, Stefa ...
-
Diener, Hans-Chr ...
-
Franzosi, Maria ...
-
Huber, Kurt
-
Reilly, Paul
-
Varrone, Jeanne
-
Yusuf, Salim
-
show less...
- Articles in the publication
-
Circulation
- By the university
-
Uppsala University